慢性阻塞性肺病(COPD) 治療市場按藥物類別、給藥途徑、通路和地區分類

2025 年全球慢性阻塞性肺病(COPD) 治療市場規模估計為 203.5 億美元，預計到 2032 年將達到 304.1 億美元，2025 年至 2032 年的年複合成長率（CAGR）為 5.9%。

數字。 2025 年慢性阻塞性肺病(COPD) 治療市場佔有率（按地區）

慢性阻塞性肺病(COPD) 是指一組導致氣流阻塞和呼吸問題的肺部疾病。這些包括肺氣腫和慢性支氣管炎。慢性阻塞性肺病的主要原因包括吸菸、接觸職場的灰塵和煙霧等肺部刺激物以及空氣污染。 COPD 的主要症狀包括呼吸短促、咳嗽、黏液（痰）和喘息。隨著 COPD 的進展，肺功能逐漸下降，導致呼吸困難。

市場動態：

全球慢性阻塞性肺病(COPD) 治療市場的成長受到多種因素的推動，例如吸煙率高、全球空氣污染水平上升、老年人口增加以及對該疾病和可用治療方案的認知不斷提高。然而，缺乏對慢性阻塞性肺病和肺癌等相關併發症的完全治療方法可能會阻礙市場的成長。製藥公司正在投資研發用於治療 COPD 的新型生物製藥，這可以為市場成長提供豐厚的機會。該公司正在開發腎上腺素自動注射器、支氣管擴張劑、吸入性皮質類固醇和聯合治療，以有效治療 COPD 症狀和急性發作。

本研究的主要特點

• 本報告對全球慢性阻塞性肺病(COPD) 治療市場進行了詳細分析，並提供了預測期 (2025-2032) 的市場規模（十億美元）和年複合成長率（CAGR%），假設基準年為 2024 年。
• 它還強調了各個領域的潛在收益成長機會，並說明了該市場的引人注目的投資提案矩陣。
• 它還提供了對市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景以及主要企業採用的競爭策略的重要見解。
• 全球慢性阻塞性肺病(COPD) 治療市場的主要企業是根據公司亮點、產品系列、關鍵亮點、業績和策略等參數列出的。
• 主要企業包括阿斯特捷利康、Orion Corporation、Mylan NV、Teva Pharmaceutical Industries Ltd.、GSK plc、諾華公司、Sunovion Pharmaceuticals, Inc、CHIESI Farmaceutici SpA、Alembic Pharmaceuticals Ltd、Verona Pharmaceuticals、Theravance Biopharma、Alembic Pharmaceuticals Ltd.和基因泰克公司。
• 本報告的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。
• 全球慢性阻塞性肺病(COPD) 治療市場迎合了該行業的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新進業者和金融分析師。
• 相關人員可以透過用於分析全球慢性阻塞性肺病(COPD) 治療市場的各種策略矩陣來促進決策。

第1章 調查目的與前提條件

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告描述
  • 市場定義和範圍
• 執行摘要
• Coherent Opportunity Map（COM）

第3章市場動態、法規與趨勢分析

• 市場動態
  • 驅動程式
  • 限制因素
  • 機會
• 影響分析
• 流行病學
• 市場趨勢
• 主要進展
• 監管情景
• 製造商收益
• 收購和合作場景
• 產品發布/核准
• 資金籌措和投資
• PEST分析
• 波特的分析

4. 全球慢性阻塞性肺病(COPD) 治療市場 - 冠狀病毒 (COVID-19) 大流行的影響

• 整體影響
• 政府舉措
• COVID-19 市場影響

第 5 章。 2020 年至 2032 年全球慢性阻塞性肺病(COPD) 治療市場按藥物類別分類（十億美元）

• 支氣管擴張劑
• 磷酸二酯酶 4 抑制劑
• 皮質類固醇
• 其他

第6章。 2020-2032 年全球慢性阻塞性肺病(COPD) 治療市場，依給藥途徑分類（十億美元）

• 口服
• 吸入

第 7 章。 2020-2032 年全球慢性阻塞性肺病(COPD) 治療市場按分銷管道分類（十億美元）

• 醫院藥房
• 零售藥局
• 網路藥局

第 8 章。 2020 年至 2032 年全球慢性阻塞性肺病(COPD) 治療市場（按地區分類）（十億美元）

• 北美洲
• 拉丁美洲
• 歐洲
• 亞太地區
• 中東
• 非洲

第9章 競爭格局

• 公司簡介
  • AstraZeneca
  • Orion Corporation
  • Mylan NV
  • Teva Pharmaceutical Industries Ltd.
  • GSK plc
  • Novartis AG
  • Sunovion Pharmaceuticals, Inc.
  • CHIESI Farmaceutici SpA
  • Alembic Pharmaceuticals Ltd
  • Verona Pharmaceuticals
  • Theravance Biopharma
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Boehringer Ingelheim International GmbH
  • Merck &Co., Inc
  • Grifols, SA
  • Almirall, SA
  • Genentech, Inc

第 10 章分析師建議

第 11 章 參考文獻與調查方法

• 參考
• 調查方法

Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market is estimated to be valued at USD 20.35 Bn in 2025 and is expected to reach USD 30.41 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032.

Figure. Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share (%), By Region 2025

Chronic obstructive pulmonary disease (COPD) refers to a group of lung diseases that cause airflow blockage and breathing-related problems. It includes emphysema and chronic bronchitis. Key causes of COPD include tobacco smoking, exposure to lung irritants in the workplace like dusts and fumes, and air pollution. The main symptoms of COPD include shortness of breath, cough, mucus (sputum) production, and wheezing. As COPD progresses, lung function deteriorates over time, resulting in breathlessness.

Market Dynamics:

Global chronic obstructive pulmonary disease (COPD) treatment market growth is driven by factors such as high prevalence of tobacco smoking, increasing air pollution levels worldwide, rising geriatric population, and a growing awareness about the disease and available therapeutic options. However, lack of complete cure for COPD and related complications like lung cancer can hamper the market growth. Pharmaceutical companies investing in research and development of novel biologic drugs for COPD can offer lucrative opportunities for the market growth. Companies are developing epinephrine auto-injectors, bronchodilators, inhaled corticosteroids and combination therapies to effectively treat COPD symptoms and exacerbations.

Key Features of the Study:

• This report provides an in-depth analysis of the global chronic obstructive pulmonary disease (COPD) treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this include AstraZeneca, Orion Corporation, Mylan N.V., Teva Pharmaceutical Industries Ltd., GSK plc, Novartis AG, Sunovion Pharmaceuticals, Inc., CHIESI Farmaceutici SpA, Alembic Pharmaceuticals Ltd, Verona Pharmaceuticals, Theravance Biopharma, F. Hoffmann-La Roche Ltd, Sanofi, Boehringer Ingelheim International GmbH, Merck & Co., Inc, Grifols, S.A., Almirall, S.A, Genentech, Inc
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global chronic obstructive pulmonary disease (COPD) treatment market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic obstructive pulmonary disease (COPD) treatment market

Detailed Segmentation-

• By Drug Class:
  • Bronchodilators
  • Beta 2-Agonists
  • Anticholinergics
  • Theophyllines
  • Phosphodiesterase Type 4 Inhibitors
  • Corticosteroids
  • Others
• By Route of Administration:
  • Oral
  • Inhalation
• By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • AstraZeneca
  • Orion Corporation
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • GSK plc
  • Novartis AG
  • Sunovion Pharmaceuticals, Inc.
  • CHIESI Farmaceutici SpA
  • Alembic Pharmaceuticals Ltd
  • Verona Pharmaceuticals
  • Theravance Biopharma
  • Hoffmann-La Roche Ltd
  • Sanofi
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc
  • Grifols, S.A.
  • Almirall, S.A
  • Genentech, Inc

Table of Contents (TOC)

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Epidemiology
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Bronchodilators
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Beta 2-Agonists
  • Anticholinergics
  • Theophyllines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Phosphodiesterase Type 4 Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Inhalation
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel, 2020 - 2032, (USD Bn)

• Overview
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region, 2020 - 2032, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, For Region, 2021-2032
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • China
    • India
    • Japan
    • ASEAN
    • Australia
    • South Korea
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2020 - 2032, (USD Bn)
    • GCC
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020 - 2032, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020 - 2032, (USD Bn)
    • North Africa
    • Central Africa
    • South Africa

9. Competitive Landscape

• Company Profiles
  • AstraZeneca*
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Orion Corporation
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Mylan N.V.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Teva Pharmaceutical Industries Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • GSK plc
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Sunovion Pharmaceuticals, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • CHIESI Farmaceutici SpA
  • Alembic Pharmaceuticals Ltd
  • Verona Pharmaceuticals
  • Theravance Biopharma
  • F. Hoffmann-La Roche Ltd
  • Sanofi
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc
  • Grifols, S.A.
  • Almirall, S.A
  • Genentech, Inc

10. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact